Filing Details

Accession Number:
0001209191-20-025308
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-04-21 18:50:08
Reporting Period:
2020-04-17
Accepted Time:
2020-04-21 18:50:08
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1346830 Cara Therapeutics Inc. CARA Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706426 Scott Terrillion C/O Cara Therapeutics, Inc.
4 Stamford Plaza, 107 Elm Street, 9Th Fl
Stamford CT 06902
Sec'y; Chief Compliance & G.c. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-04-17 8,334 $0.00 41,103 No 4 A Direct
Common Stock Disposition 2020-04-21 2,721 $15.56 38,382 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Footnotes
  1. Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on April 17, 2020. The vested shares represent the total number of remaining shares subject to the award. Each RSU represents the contingent right to receive one share of common stock of the Issuer.
  2. This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting and of the RSUs reported herein as described in greater detail in footnote (1), and does not represent a discretionary trade by the Reporting Person.
  3. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding as described in footnote (2).